Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Diosmin/Hesperidin (90/10) 500 mg
NCT05158192Phase 1Completed
- Sponsor
- Laboratorios Andromaco S.A.
- Start
- Nov 2021
- Primary completion
- Dec 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of diosmin and hesperidin in chronic venous insufficiency (CVI) and Hemorrhoids (2 arms), sponsored by Laboratorios Andromaco S.A. Primary endpoints: Area under the plasma concentration-time curve from 0 to 72 hours, Area under the plasma concentration-time curve from 0 to t hours at 72 hours and 1 more. Started Nov 2021; status: completed.
02
Drugs
diosminhesperidin
03
Conditions
chronic venous insufficiency (CVI)Hemorrhoids
Beyond the preview
Go deeper on NCT05158192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05158192.